Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Wednesday, November 19, 2008, 4:37AM ET - U.S. Markets open in 4 hours and 53 minutes. Dow Up 1.83% Nasdaq  0.00%
Genomic Health Inc. (GHDX)On Nov 18: 18.86   0.00 (0.00%)  
MORE ON GHDX
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Genomic Health Inc.
301 Penobscot Drive
Redwood City, CA 94063
United States - Map
Phone: 650-556-9300
Fax: 650-556-1132
Web Site: http://www.genomichealth.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Laboratories & Research
Full Time Employees:288

BUSINESS SUMMARY 
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer that enable physicians and patients to make individualized treatment decisions in the United States. The company’s Oncotype DX is a clinical laboratory test, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence and the likelihood of chemotherapy benefit. It offers Oncotype DX as a clinical laboratory service, where it analyses the expression levels of 21 genes in tumor tissue samples in its laboratory and provide physicians with a quantitative gene expression profile expressed as a single quantitative Recurrence Score. The Oncotype DX report also includes measurements of quantitative gene expression for estrogen receptor (ER) and progesterone receptor (PR), which are used in the calculation of the Recurrence Score result. In addition, the company is in the early development phase to develop tests to predict the likelihood of response to the epidermal growth factor receptor inhibitor class of drugs, as well as for a product to predict the likelihood of taxane benefit in breast cancer patients. Further, it has products in various stages of development for other cancers, including colon cancer, prostate cancer, renal cell cancer, non-small cell lung cancer, and melanoma. The company has collaborative agreements with Aventis, Inc. and the Eastern Cooperative Oncology Group to investigate the ability of gene expression in FPE tissues to predict the likelihood of response to adjuvant chemotherapy, including the taxane Taxotere, in patients with early breast cancer and zero to three involved lymph nodes; and Bristol-Myers Squibb Company and ImClone Systems Incorporated to develop a genomic test to predict the likelihood of response to Erbitux in colorectal cancer. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Genomic Health Inc.


    CORPORATE GOVERNANCE 
    Genomic Health Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Nov-08 is better than 37.7% of Russell 3000 companies and 43.9% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Randy W. Scott Ph.D., 50
    Co-founder, Chairman and Chief Exec. Officer
    $ 305.00K $ 0
    Ms. Kimberly J. Popovits , 49
    Pres, Chief Operating Officer
    $ 365.00K $ 688.00K
    Mr. G. Bradley Cole , 52
    Chief Financial Officer, Principal Accounting Officer, Exec. VP of Operations and Sec.
    $ 311.00K $ 0
    Dr. Steven Shak M.D., 57
    Chief Medical Officer
    $ 340.00K $ 0
    Dr. Joffre B. Baker Ph.D., 60
    Chief Scientific Officer
    $ 335.00K $ 0
    Dollar amounts are as of 31-Dec-07 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis